Literature DB >> 12358411

Effect of maze procedure in patients with atrial fibrillation undergoing valve replacement.

Ko Bando1, Junjiro Kobayashi, Yoshikado Sasako, Osamu Tagusari, Kazuo Niwaya, Soichiro Kitamura.   

Abstract

BACKGROUND AND AIMS OF THE STUDY: The study aim was to elucidate the impact of the maze procedure on late outcome after valve replacement.
METHODS: Between 1992 and 2000, 241 patients underwent the maze procedure combined with valve replacement. Patients were allocated to three groups: aortic valve replacement (AVR/maze, n = 16); mitral valve replacement (MVR/maze, n = 148); and combined aortic and mitral valve replacement (DVR/maze, n = 77).
RESULTS: Mean follow up was 3.9 +/- 2.3 years. Hospital mortality was 0% in the AVR/maze group, 2.0% (n = 3) in the MVR/maze group, and 3.9% (n = 3) in the DVR/maze group. Elimination of atrial fibrillation (AF) at discharge was achieved in 74.3-75.9% of cases. Freedom from recurrence of AF/atrial flutter was 71.2% in the AVR/maze group, 68.2% in the MVR/maze group, and 64.0% in the DVR/maze group at five-year follow up. By multivariate analysis, risk factors for recurrence of AF/atrial flutter included preoperative enlarged left atrial dimension >70 mm, decreased postoperative fractional shortening <30%, and absence of postoperative left atrial contraction. Freedom from stroke was 93.6% in patients who achieved regular rhythm (normal sinus rhythm or junctional rhythm), and 80.9% in those with recurrence of AF at five years after surgery (p = 0.03).
CONCLUSION: The combined maze procedure and valve replacement is safe and effective in selected patients. Restoration of regular rhythm significantly reduced the incidence of late stroke.

Entities:  

Mesh:

Year:  2002        PMID: 12358411

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  7 in total

1.  Impact of epicardial ablation of concomitant atrial fibrillation on atrial natriuretic peptide levels and atrial function in 6 months follow-up: does preoperative ANP level predict outcome of ablation?

Authors:  Marek Pizon; Norbert Friedel; Monika Pizon; Miriam Freundt; Michael Weyand; Richard Feyrer
Journal:  J Cardiothorac Surg       Date:  2013-11-28       Impact factor: 1.637

Review 2.  The Cox-Maze procedure: history, results, and predictors for failure.

Authors:  Niv Ad
Journal:  J Interv Card Electrophysiol       Date:  2007-12       Impact factor: 1.900

3.  Modified Maze Procedure for Atrial Fibrillation as an Adjunct to Elective Cardiac Surgery: Predictors of Mid-Term Recurrence and Echocardiographic Follow-Up.

Authors:  Claudia Loardi; Francesco Alamanni; Fabrizio Veglia; Claudia Galli; Alessandro Parolari; Marco Zanobini
Journal:  Tex Heart Inst J       Date:  2015-08-01

4.  Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study.

Authors:  Petr Budera; Zbyněk Straka; Pavel Osmančík; Tomáš Vaněk; Štěpán Jelínek; Jan Hlavička; Richard Fojt; Pavel Červinka; Michal Hulman; Michal Šmíd; Marek Malý; Petr Widimský
Journal:  Eur Heart J       Date:  2012-08-28       Impact factor: 29.983

5.  Clinical Effect of Left Ventricular Dysfunction in Patients with Mitral Stenosis after Mitral Valve Replacement.

Authors:  Kwon Jae Park; Jong Soo Woo; Jong Yoon Park; Jae Hwa Jung
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2016-10-05

Review 6.  Maze Procedures for Atrial Fibrillation, From History to Practice.

Authors:  Charles Kik; Ad J J C Bogers
Journal:  Cardiol Res       Date:  2011-09-20

7.  Design and rationale of the PRAGUE-12 trial: a large, prospective, randomized, multicenter trial that compares cardiac surgery with left atrial surgical ablation with cardiac surgery without ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation.

Authors:  Zbyněk Straka; Petr Budera; Pavel Osmančík; Tomáš Vaněk; Michal Hulman; Michal Smíd; Marek Malý; Petr Widimský
Journal:  Clin Cardiol       Date:  2012-12-24       Impact factor: 2.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.